PL2403605T3 - Kompozycje zawierające przeciwciało specyficzne względem aP2 albo jego fragment do zastosowania w leczeniu cukrzycy, nietolerancji glukozy lub insulinooporności wywołanej otyłością - Google Patents
Kompozycje zawierające przeciwciało specyficzne względem aP2 albo jego fragment do zastosowania w leczeniu cukrzycy, nietolerancji glukozy lub insulinooporności wywołanej otyłościąInfo
- Publication number
- PL2403605T3 PL2403605T3 PL10707783T PL10707783T PL2403605T3 PL 2403605 T3 PL2403605 T3 PL 2403605T3 PL 10707783 T PL10707783 T PL 10707783T PL 10707783 T PL10707783 T PL 10707783T PL 2403605 T3 PL2403605 T3 PL 2403605T3
- Authority
- PL
- Poland
- Prior art keywords
- obesity
- fragment
- compositions
- specific antibody
- insulin resistance
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Toxicology (AREA)
- Zoology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20925109P | 2009-03-05 | 2009-03-05 | |
| US29917010P | 2010-01-28 | 2010-01-28 | |
| PCT/US2010/026305 WO2010102171A2 (en) | 2009-03-05 | 2010-03-05 | Secreted ap2 and methods of inhibiting same |
| EP10707783.6A EP2403605B1 (en) | 2009-03-05 | 2010-03-05 | Compositions comprising an aP2-specific antibody or a fragment thereof for use in treating diabetes, glucose intolerance or obesity-induced insulin resistance |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2403605T3 true PL2403605T3 (pl) | 2016-01-29 |
Family
ID=42312973
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL10707783T PL2403605T3 (pl) | 2009-03-05 | 2010-03-05 | Kompozycje zawierające przeciwciało specyficzne względem aP2 albo jego fragment do zastosowania w leczeniu cukrzycy, nietolerancji glukozy lub insulinooporności wywołanej otyłością |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US20120134998A1 (pl) |
| EP (2) | EP2403605B1 (pl) |
| JP (4) | JP5984396B2 (pl) |
| CN (3) | CN107141353A (pl) |
| AU (2) | AU2010221182B2 (pl) |
| BR (1) | BRPI1013358A2 (pl) |
| CA (1) | CA2753991C (pl) |
| DK (1) | DK2403605T3 (pl) |
| ES (1) | ES2542737T3 (pl) |
| HK (1) | HK1212923A1 (pl) |
| HR (1) | HRP20150807T1 (pl) |
| PL (1) | PL2403605T3 (pl) |
| PT (1) | PT2403605E (pl) |
| SI (1) | SI2403605T1 (pl) |
| SM (1) | SMT201500190B (pl) |
| WO (1) | WO2010102171A2 (pl) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120134998A1 (en) | 2009-03-05 | 2012-05-31 | President And Fellows Of Harvard College | Secreted ap2 and methods of inhibiting same |
| CN103665139A (zh) * | 2013-11-29 | 2014-03-26 | 中国药科大学 | 一种脂肪细胞型脂肪酸结合蛋白及其单克隆抗体的制备和应用 |
| JP6223376B2 (ja) | 2014-03-24 | 2017-11-01 | 花王株式会社 | Ｇｉｐ上昇抑制剤の評価又は選択方法 |
| MX2017013807A (es) | 2015-04-30 | 2018-03-15 | Harvard College | Anticuerpos anti-proteina de union al lipido de adipocito humana (ap2) y agente de union al antigeno para tratar trastornos metabolicos. |
| US11320441B2 (en) | 2015-06-10 | 2022-05-03 | Children's National Medical Center | Adipocyte-derived exosomes, and compositions, kits, and methods of using the same for detection and screening |
| JP6558729B2 (ja) * | 2015-06-15 | 2019-08-14 | 北海道公立大学法人 札幌医科大学 | 糸球体障害の検査方法 |
| BR112018076703A2 (pt) * | 2016-06-27 | 2019-04-02 | President And Fellows Of Harvard College | compostos úteis para tratar distúrbios metabólicos |
| US10792119B2 (en) | 2017-05-22 | 2020-10-06 | Ethicon Llc | Robotic arm cart and uses therefor |
| US10856948B2 (en) | 2017-05-31 | 2020-12-08 | Verb Surgical Inc. | Cart for robotic arms and method and apparatus for registering cart to surgical table |
| WO2018227200A1 (en) | 2017-06-09 | 2018-12-13 | President And Fellows Of Harvard College | Method to identify compounds useful to treat dysregulated lipogenesis, diabetes, and related disorders |
| US10913145B2 (en) | 2017-06-20 | 2021-02-09 | Verb Surgical Inc. | Cart for robotic arms and method and apparatus for cartridge or magazine loading of arms |
| CN109971761B (zh) * | 2019-04-12 | 2022-07-29 | 宁夏大学 | 脂肪酸结合蛋白4的小干扰rna及其应用 |
| KR20230031322A (ko) | 2020-06-27 | 2023-03-07 | 크레센타 바이오사이언시즈 | 세포 물질대사를 조정하는 화합물의 조성물 및 사용 방법 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1507C (da) | 1898-03-21 | Peter Holger Hansen | Fremgangsmaade til Fremstilling af en hornagtig Masse af Kasein. | |
| DK4360C (da) | 1901-11-18 | Bethlehem Steel Corp | Anordning til Regulering af Temperaturen i et Metalbad til Brug ved Hærdning. | |
| EP0651818B1 (en) * | 1990-05-16 | 1999-01-07 | Dana Farber Cancer Institute | Immunogenic peptides, antibodies and uses thereof relating to cd4 receptor binding |
| US5889167A (en) | 1996-05-22 | 1999-03-30 | Merck & Co., Inc. | Synthetic glucagon binding proteins |
| WO2000015229A1 (en) * | 1998-09-17 | 2000-03-23 | Bristol-Myers Squibb Company | METHOD FOR TREATING DIABETES EMPLOYING AN aP2 INHIBITOR AND COMBINATION |
| WO2000047734A1 (en) * | 1999-02-12 | 2000-08-17 | President And Fellows Of Harvard College | Inhibiting formation of atherosclerotic lesions |
| US6548529B1 (en) * | 1999-04-05 | 2003-04-15 | Bristol-Myers Squibb Company | Heterocyclic containing biphenyl aP2 inhibitors and method |
| US7390824B1 (en) * | 1999-09-07 | 2008-06-24 | Bristol-Myers Squibb Company | Method for treating diabetes employing an aP2 inhibitor and combination |
| EP1409536A2 (en) * | 2001-02-12 | 2004-04-21 | Curagen Corporation | Human proteins and nucleic acids encoding same |
| US6919323B2 (en) * | 2001-07-13 | 2005-07-19 | Bristol-Myers Squibb Company | Pyridazinone inhibitors of fatty acid binding protein and method |
| AU2002348276A1 (en) * | 2001-11-16 | 2003-06-10 | Bristol-Myers Squibb Company | Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein |
| TW200518768A (en) * | 2003-11-17 | 2005-06-16 | Pepgen Corp | Methods for treatment of obesity and for promotion of weight loss |
| DE102006034607A1 (de) * | 2005-07-21 | 2007-01-25 | Biovendor Laboratory Medicine, Inc. | Verfahren zur Bestimmung der Konzentration der adipozytären Form des fatty acid binding protein (A-FABP, FABP4, P2) |
| DE502006006990D1 (de) * | 2005-07-21 | 2010-07-01 | Biovendor Lab Medicine Inc | VERFAHREN ZUR BESTIMMUNG DER KONZENTRATION DER ADIPOZYTAREN FORM DES FATTY ACID BINDUNG PROTEIN (A-FABP, FABP4, aP2) |
| EP2350266B1 (en) | 2008-11-20 | 2015-07-29 | Mesoblast, Inc. | Method for treating or preventing a pancreatic dysfunction |
| US20120134998A1 (en) * | 2009-03-05 | 2012-05-31 | President And Fellows Of Harvard College | Secreted ap2 and methods of inhibiting same |
-
2010
- 2010-03-05 US US13/203,880 patent/US20120134998A1/en not_active Abandoned
- 2010-03-05 AU AU2010221182A patent/AU2010221182B2/en active Active
- 2010-03-05 CN CN201710076983.0A patent/CN107141353A/zh active Pending
- 2010-03-05 CA CA2753991A patent/CA2753991C/en active Active
- 2010-03-05 CN CN2010800198008A patent/CN102639149A/zh active Pending
- 2010-03-05 BR BRPI1013358A patent/BRPI1013358A2/pt not_active Application Discontinuation
- 2010-03-05 PT PT107077836T patent/PT2403605E/pt unknown
- 2010-03-05 JP JP2011553125A patent/JP5984396B2/ja active Active
- 2010-03-05 SI SI201030995T patent/SI2403605T1/sl unknown
- 2010-03-05 DK DK10707783.6T patent/DK2403605T3/en active
- 2010-03-05 WO PCT/US2010/026305 patent/WO2010102171A2/en active Application Filing
- 2010-03-05 PL PL10707783T patent/PL2403605T3/pl unknown
- 2010-03-05 CN CN201710076996.8A patent/CN107149679B/zh active Active
- 2010-03-05 EP EP10707783.6A patent/EP2403605B1/en active Active
- 2010-03-05 ES ES10707783.6T patent/ES2542737T3/es active Active
- 2010-03-05 EP EP15154201.6A patent/EP2898898A1/en active Pending
-
2015
- 2015-03-20 JP JP2015057399A patent/JP5966039B2/ja active Active
- 2015-07-23 HR HRP20150807TT patent/HRP20150807T1/hr unknown
- 2015-08-06 SM SM201500190T patent/SMT201500190B/xx unknown
-
2016
- 2016-01-29 HK HK16101022.2A patent/HK1212923A1/zh unknown
- 2016-04-07 US US15/093,508 patent/US9879078B2/en active Active
- 2016-04-07 JP JP2016076997A patent/JP6301995B2/ja active Active
- 2016-07-04 JP JP2016132195A patent/JP2016180000A/ja active Pending
- 2016-10-27 AU AU2016250423A patent/AU2016250423A1/en not_active Abandoned
-
2017
- 2017-12-21 US US15/851,040 patent/US10882901B2/en active Active
-
2020
- 2020-11-23 US US17/102,329 patent/US11685774B2/en active Active
-
2023
- 2023-06-26 US US18/341,404 patent/US20240209072A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2403605T1 (sl) | Sestavki, ki obsegajo aP2-specifično protitelo ali njegov fragment, za uporabo pri zdravljenju diabetesa, intolerance za glukozo ali z debelostjo povzročene inzulinske rezistence | |
| HRP20180667T1 (hr) | Protutijelo agonista kloto-beta za uporabu u liječenju dijabetesa ili otpornosti na inzulin | |
| EP2424507A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INSULIN AND DIABETES RESISTANCE | |
| EP2345893A4 (en) | MEASURING DEVICE, INSULIN PERFUSION DEVICE AND ITS CONTROL METHOD, MEASUREMENT TECHNIQUE, AND PROGRAM | |
| EP2120959A4 (en) | METHOD AND COMPOSITIONS FOR TREATING INSULIN RESISTANCE, DIABETES AND DIABETES-BASED DYSLIPIDEMIA | |
| HK1161275A1 (en) | Halogen-stabilized insulin | |
| SI2252312T1 (sl) | Postopki za preprečevanje ali zdravljenje insulinske rezistence | |
| SI2461830T1 (sl) | Antiproliferativne spojine, njihovi konjugati, njihovi postopki, in njihova uporaba | |
| PL389427A1 (pl) | Automatyczny aplikator, zwłaszcza do insuliny | |
| PL2442814T3 (pl) | Bifidobacteria do leczenia cukrzycy i pokrewnych chorób | |
| HK1163569A1 (en) | Processing blood | |
| EP2309225A4 (en) | POSITION MEASUREMENT METHOD, POSITION MEASUREMENT DEVICE AND PROGRAM | |
| EP2272015A4 (en) | OPEN FRAMEWORK FOR INTEGRATING AND ASSIGNING CONTENT OBJECTS AND INTERACTION WITH THEM | |
| EP2328639A4 (en) | MEDICAL INJECTOR WITH DOSING BUTTON ACTUATION FOR AUTOMATIC RECONSTITUTION | |
| AP2010005499A0 (en) | Improvements in feedwells. | |
| PL2354161T3 (pl) | Przeciwciało anty -NR10 i jego zastosowanie | |
| EP2001362A4 (en) | QUANTITATIVE OPTOACUSTIC TOMOGRAPHY WITH REINFORCED CONTRASTS | |
| PL2257493T3 (pl) | Ramię załadowcze z bezpośrednią regulacją, w szczególności regulacją proporcjonalną | |
| EP2045596A4 (en) | X-RAY INSPECTION DEVICE AND X-RAY INSPECTION PROGRAM | |
| EP2335746A4 (en) | MEDICAL DEVICE, MEDICAL MATERIAL, AND METHODS OF PRODUCTION THEREOF | |
| EP2318026A4 (en) | COMPOSITION FOR CONTROLLING BLOOD SUGAR INCREASE | |
| EP2169559A4 (en) | CONTENT DISTRIBUTION DEVICE, CONTENT DISTRIBUTION METHOD, AND CONTENT DISTRIBUTION PROGRAM | |
| EP2281191A4 (en) | BILIRUBIN REFERENCE MATERIAL AT HÄMOGLOBINBASIS | |
| SI2354161T1 (sl) | Anti-NR10 protitelo in njegova uporaba | |
| HK1120806A1 (en) | Agent for improving insulin resistance |